Providing oncology drug developers with the successful delivery of early phase oncology studies.
Slough, Berkshire, United Kingdom: Simbec-Orion announced a charter agreement between the Oncodistinct Network and Simbec-Orion. The agreement strengthens the relationships between Simbec-Orion and the Oncodistinct network of oncology sites, who partner in operations and scientific expertise in the design and conduct of international early phase oncology trials.
“As a full-service agile Oncology CRO, dedicated to high quality delivery, the partnership between the Oncodistinct Network and Simbec-Orion provides benefits to both sponsors and patients,” says Fabrice Chartier CEO at Simbec-Orion.
The Oncodistinct network is committed to accelerating oncology drug development and innovative strategies in clinical and translational research.
“This partnership with Simbec-Orion aligns with our network’s principles and activities, and underscores our commitment to innovative clinical research” says Professor Ahmad Awada from Oncodistinct.
The benefits of this agreement will include:
- Streamlining of process and communication between sites, Simbec-Orion and sponsors to drive efficiencies in the setup and delivery of trials including the reduction of administrative burden in confidentiality agreements, feasibility efforts and contract negotiation
- Commitment to fast-track feasibility within five working days of receipt
- Expert and strategic advice on study design, protocol review and development
Simbec-Orion is a responsive and agile full-service CRO, with specialist expertise in clinical pharmacology, oncology and rare diseases. Perfectly structured, we provide full-service clinical development solutions for small and mid-size drug developers – headed up by a centralised leadership team. With a focus on tailormade and scalable solutions, we’ll adapt our delivery style, communications and operations to suit the demands of your project, helping you achieve your clinical and commercial objectives. Because our goal is the same as yours; to improve patients’ lives.
About Oncodistinct Network:
Created at the initiative of several cancer centres in and outside of Europe, the Oncodistinct Network is a multidisciplinary group of investigators with an expertise in early drug development and clinical research.
Together, we aim to address the current challenges in oncology and improve patients’ outcomes by developing innovative clinical studies and accelerating the development of anti-cancer drugs in solid tumors, particularly in settings with unmet medical needs.
As of today, the network brings together more than 25 cancer centres and university hospitals. Oncodistinct is built on tight collaborations between oncologists, organ specialists, radiotherapists and scientists of each Oncodistinct site as well as pharmaceutical companies.